Abstract
BackgroundEzetimibe (EZ) is a potent inhibitor of cholesterol absorption by enterocytes. Although EZ minimally affects fat absorption, it is unknown if EZ affects the secretion of incretins glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) during triglyceride (TG) absorption.AimWe determined if EZ influences the lymphatic secretion of incretins stimulated by the ingestion of Ensure.MethodsIn SD rats, the mesenteric lymph duct was cannulated and a duodenal infusion tube was installed. EZ (0.67 mg/kg) or saline was infused duodenally 2 h prior to the feeding of a 3 ml bolus dose of Ensure (4.43 kcal). To determine glucose, TG, cholesterol, GIP, and GLP‐1 concentrations, lymph samples were collected 2 h before and 2 h after infusion of Ensure.ResultsEZ did not affect lymph flow, glucose or TG output stimulated by Ensure compared with the control rats. As expected, EZ did significantly reduce lymphatic cholesterol output. Interestingly, EZ significantly reduced the stimulation of lymphatic secretion of GIP and GLP‐1 induced by Ensure.ConclusionsReduced secretion of GIP and GLP‐1 by the enteroendocrine cells is associated with decreased cholesterol secretion in EZ‐treated rats. Moreover, this response of intestinal incretin secretion is independent from the uptake of dietary TG. The mechanism involved remains to be elucidated. This work was supported by NIH.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have